Operating cash flow of -$3.2M in 2026Q3 and cumulative operating cash burn of roughly $82M across the analyzed quarters indicate persistent cash consumption, warranting investor attention to the trajectory of the $52.7M cash balance.
Pulmonx Corporation (LUNG) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -25.58M | -32.45M | -31.54M | -37.61M | -45.14M | -41.43M | -30.63M | -20.77M | -18.39M |
| Operating CF Margin % | - | -35.85% | -37.64% | -54.77% | -84.11% | -85.57% | -93.58% | -63.71% | -91.95% |
| Operating CF Growth % | 47.54% | -2.88% | 16.15% | 16.67% | -8.95% | -35.24% | -47.52% | -12.89% | - |
| Net Income | -42.55M | -54M | -56.39M | -60.84M | -58.92M | -48.66M | -32.23M | -20.7M | -18.48M |
| Depreciation & Amortization | 1.29M | 1.05M | 1.49M | 1.55M | 1.51M | 867K | 483K | 365K | 270K |
| Stock-Based Compensation | 7.31M | 0 | 22.95M | 22.1M | 0 | 0 | 3.2M | 364K | 366K |
| Deferred Taxes | -10K | 0 | 0 | 0 | 49K | -6K | 0 | 746K | 936K |
| Other Non-Cash Items | 11.36M | 22.43M | 2.11M | 2.14M | 19.29M | 14.21M | 2.71M | 864K | 36K |
| Working Capital Changes | -2.98M | -1.93M | -1.7M | -2.56M | -7.06M | -7.84M | -4.79M | -2.4M | -1.52M |
| Change in Receivables | 1.43M | 1.07M | -1.31M | -3.1M | -2.19M | -2.43M | 1.46M | -2.52M | -262K |
| Change in Inventory | -1.44M | -765K | -229K | 918K | -3.64M | -6.46M | -5.05M | -2.61M | -1.25M |
| Change in Payables | -1.88M | 270K | 2.28M | -345K | 247K | 87K | 592K | 524K | -648K |
| Cash from Investing | -31K | 30.48M | 17.48M | -2.01M | -4.22M | -46.26M | 12.69M | -14.23M | 200K |
| Capital Expenditures | -31K | -452K | -1.45M | -807K | -1.32M | -3.67M | -911K | -720K | -316K |
| CapEx % of Revenue | 0.03% | 0.5% | 1.73% | 1.18% | 2.46% | 7.58% | 2.78% | 2.21% | 1.58% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.51M | 16K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13.51M | 16K |
| Cash from Financing | 1.73M | 903K | 1.36M | 21.4M | 2.47M | 4.5M | 234.83M | 45.62M | 12.11M |
| Debt Issued (Net) | 1.18M | -100K | -95K | 19.91M | -87K | 0 | 32.99M | 6M | 12M |
| Equity Issued (Net) | 554K | 1M | 0 | 0 | 2.56M | 4.5M | 201.39M | 39.67M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -27K | -26K | 0 | -12K | 0 |
| Other Financing | 0 | 0 | 1.46M | 1.49M | 0 | 0 | 446K | -52K | 114K |
| Net Change in Cash | -23.86M | -1.15M | -12.62M | -18.18M | -46.74M | -83.08M | 217.03M | 10.64M | -5.93M |
| Free Cash Flow | -25.61M | -32.9M | -32.98M | -38.42M | -46.45M | -45.1M | -31.54M | -21.48M | -18.71M |
| FCF Margin % | -28.85% | -36.35% | -39.37% | -55.94% | -86.57% | -93.15% | -96.37% | -65.92% | -93.53% |
| FCF Growth % | 21.49% | 0.26% | 14.14% | 17.3% | -3% | -42.97% | -46.82% | -14.83% | - |
| FCF per Share | -0.59 | -0.81 | -0.84 | -1.01 | -1.25 | -1.25 | -0.88 | -0.61 | -0.90 |
| FCF Conversion (FCF/Net Income) | 0.60x | 0.60x | 0.56x | 0.62x | 0.77x | 0.85x | 0.95x | 1.00x | 1.00x |
| Interest Paid | 0 | 0 | 3.48M | 2.98M | 0 | 0 | 3.06M | 1.4M | 1.36M |
| Taxes Paid | 0 | 0 | 556K | 471K | 0 | 0 | 259K | 196K | 226K |
Quick answers to the most common questions about buying LUNG stock.
Pulmonx Corporation (LUNG) generated $-32.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Pulmonx Corporation (LUNG) reported negative free cash flow of $32.9M in 2025, indicating capital requirements exceeded cash from operations.
Pulmonx Corporation (LUNG) spent $0.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Metrics are mathematically derived from official filings.
Cash Losses Track Accounting Losses
Based on Pulmonx's reported quarterly figures, operating cash flow of -$3.2M in 2026Q3 against net income of -$8.4M produced an OCF/NI ratio of 0.38, meaning cash burn is smaller than the accounting loss but still persistently negative across all ten quarters analyzed.
The conversion ratio has moved from 0.92 in 2025Q1 to 0.38 in 2026Q3, which suggests that non-cash add-backs such as stock-based compensation and depreciation are absorbing a growing share of the reported loss. Stock-based compensation of $3.6M in the latest quarter accounts for a meaningful portion of that gap, so the net loss alone understates the underlying cash consumption of the business. The improving ratio should not be read as an earnings quality improvement, since operations consumed cash in every period shown.
Free Cash Flow Deeply Negative Throughout
As reported in the financial statements, Pulmonx's free cash flow margin improved from -60.0% in 2025Q1 to -14.0% in 2026Q3, yet the company has not generated positive free cash flow in any of the ten quarters analyzed.
The margin improvement is substantial, but it appears driven by revenue growth and cost discipline rather than any structural shift toward cash generation. Capital expenditure remains under 2% of revenue, so the burn is almost entirely operating in nature. Investors should monitor whether the margin trend continues toward breakeven, since the current trajectory still implies reliance on external funding sources that are not detailed in the supplied data.
Working Capital Swings Mask Underlying Burn
Based on Pulmonx's reported figures, working capital changes swung from a $4.8M outflow in 2025Q1 to a $4.7M inflow in 2025Q2, indicating that the timing of receivables and payables is driving meaningful quarter-to-quarter volatility in operating cash flow.
These swings are large relative to the company's cash flow base and suggest that operating cash flow in any single quarter may not reflect the sustainable run rate. The pattern warrants further investigation into collection timing and inventory management, since a reversal of the recent inflow would likely widen the cash burn. Interpretation should rely on multi-quarter averages rather than individual periods.
Asset-Light Model Limits Reinvestment Needs
According to recent SEC filings, Pulmonx's capital expenditure has fallen from 2.3% of revenue in 2024Q2 to effectively zero in 2026Q3, reflecting an asset-light operating model with minimal physical reinvestment requirements.
Low capital intensity means the company's cash needs are driven by operating expenses rather than fixed asset investment, which is consistent with a device company that may rely on outsourced manufacturing and direct sales. Depreciation of $622K in 2026Q3 is not being matched by meaningful replacement spending, which may indicate a small asset base rather than an underinvestment concern. The primary cash question is therefore operating burn rather than reinvestment.
Cumulative Cash Burn Exceeds Reported Losses
Based on Pulmonx's reported figures, cumulative operating cash flow across the ten quarters analyzed totals roughly -$82M, reflecting sustained operating outflows partially offset by non-cash charges embedded in the reported net loss.
The cumulative cash burn is the most material signal in the dataset, as it shows operations consumed cash in every quarter without a single period of positive free cash flow. Stock-based compensation provides non-cash relief to the income statement, but it represents a real economic cost to shareholders through dilution. Investors should monitor the balance between cash on hand and the pace of continued burn to assess how long current resources can sustain operations.
Margin Recovery Could Narrow the Burn
Based on Pulmonx's reported figures, the free cash flow margin has improved by roughly 46 percentage points since 2025Q1, and if that trajectory continued, the company could approach breakeven, though the supplied data does not establish that outcome.
A counter-view is that the operating cash burn is narrowing faster than the loss-based metrics suggest, given that the FCF margin moved from -60.0% to -14.0% over the period shown. If revenue growth and gross margin stability persist, the burn could compress further and reduce funding pressure. This interpretation is inferential, however, because the supplied data covers only ten quarters and does not include management guidance or external financing details.